Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9961193 | Journal of the American College of Cardiology | 2005 | 8 Pages |
Abstract
Metoprolol CR/XL significantly reduced mortality and hospitalizations independent of resting baseline HR, achieved HR, and change in HR. Achieved HR and change in HR during follow-up were closely related to baseline HR; therefore, it was not possible to answer the question posed. Instead, one has to apply a very simple rule: aim for the target beta-blocker dose used in clinical trials, and strive for the highest tolerated dose in all patients with heart failure, regardless of baseline and achieved HR.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Lars MD, PhD, John MD, PhD, Prakash MD, FACC, Ã
ke MD, PhD, Kenneth MD, DMSci, FESC, Uri MD, PhD, Stephen MD, Andrew MD, Hans PhD, Georgina PhD, John MD, PhD, for the MERIT-HF Study Group for the MERIT-HF Study Group,